Marvel Biosciences Corp.
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company's lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer's disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hal… Read more
Marvel Biosciences Corp. (MBCOF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of October 2025: 0.049x
Based on the latest financial reports, Marvel Biosciences Corp. (MBCOF) has a cash flow conversion efficiency ratio of 0.049x as of October 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-178.46K) by net assets ($-3.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Marvel Biosciences Corp. - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Marvel Biosciences Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Marvel Biosciences Corp. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Marvel Biosciences Corp. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Acrux Limited
PINK:ARUXF
|
-4.086x |
|
VIOL Co. Ltd
KQ:335890
|
0.042x |
|
Stenocare AS
CO:STENO
|
-0.316x |
|
Semilux International Ltd. Ordinary Shares
NASDAQ:SELX
|
-0.064x |
|
Neurobo Pharmaceuticals Inc
NASDAQ:NRBO
|
-0.431x |
|
Synertec Corporation Ltd
AU:SOP
|
-0.602x |
|
Digicontent Limited
NSE:DGCONTENT
|
0.197x |
|
NSX Ltd
AU:NSX
|
0.587x |
Annual Cash Flow Conversion Efficiency for Marvel Biosciences Corp. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Marvel Biosciences Corp. from 2020 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-07-31 | $-4.01 Million | $-1.15 Million | 0.287x | -31.21% |
| 2024-07-31 | $-2.83 Million | $-1.18 Million | 0.417x | -46.11% |
| 2023-07-31 | $-1.72 Million | $-1.33 Million | 0.775x | +106.90% |
| 2022-07-31 | $195.54K | $-2.19 Million | -11.220x | -1828.46% |
| 2021-07-31 | $2.36 Million | $-1.37 Million | -0.582x | +87.16% |
| 2020-07-31 | $118.80K | $-538.53K | -4.533x | -- |